- Home
- PRLD vs AVTX Comparison
PRLD vs AVTX Comparison
Compare PRLD & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | AVTX |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.2M | 328.4M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PRLD | AVTX |
|---|---|---|
| Price | $3.95 | $13.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $5.67 | ★ $40.57 |
| AVG Volume (30 Days) | 298.3K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.21 | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | $12,140,000.00 | ★ $27,813,137.00 |
| Revenue This Year | $320.10 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 73.43 | ★ 2312.27 |
| 52 Week Low | $0.75 | $4.46 |
| 52 Week High | $5.54 | $24.27 |
Technical Indicators
Market Signals| Indicator | PRLD | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.00 | 35.58 |
| Support Level | $3.92 | $13.22 |
| Resistance Level | $4.10 | $15.63 |
| Average True Range (ATR) | 0.29 | 0.96 |
| MACD | -0.01 | -0.40 |
| Stochastic Oscillator | 59.44 | 16.05 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.